Cargando…
Hepatitis C virus micro-elimination: Where do we stand?
Hepatitis C virus (HCV) elimination by 2030, using direct-acting antiviral treatments, has been promoted by the World Health Organization. This achievement is not attainable, however, particularly after the 2020 pandemic of the coronavirus disease 2019. Consequently, the more realistic objective of...
Autores principales: | Mangia, Alessandra, Cotugno, Rosa, Cocomazzi, Giovanna, Squillante, Maria Maddalena, Piazzolla, Valeria |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8072193/ https://www.ncbi.nlm.nih.gov/pubmed/33967553 http://dx.doi.org/10.3748/wjg.v27.i16.1728 |
Ejemplares similares
-
Liver transplantation for hepatocellular carcinoma: Where do we stand?
por: Santopaolo, Francesco, et al.
Publicado: (2019) -
Viscoelastic tests in liver disease: where do we stand now?
por: Buliarca, Alina, et al.
Publicado: (2021) -
Role of endoscopic ultrasound in liver disease: Where do we stand in 2017?
por: Saraireh, Hamzeh A, et al.
Publicado: (2017) -
Durability of immune response to SARS-CoV-2 vaccination in patients with liver cirrhosis (LC) as compared to healthcare workers (HW)
por: Mangia, Alessandra, et al.
Publicado: (2022) -
Screening and surveillance methods for dysplasia in inflammatory bowel disease patients: Where do we stand?
por: Galanopoulos, Michail, et al.
Publicado: (2018)